Frexalimab

Frexalimab is Sanofi's next-generation anti-CD40L antibody now in Phase 3 for relapsing multiple sclerosis (FREXALT, NCT06141473, active comparator teriflunomide) and non-relapsing secondary progressive MS (FREVIVA, NCT06141486, placebo-controlled, n=858) [2][9], backed by a Phase 2 signal that showed an 89% reduction in new gadolinium-enhancing brain lesions relative to placebo at the 1200 mg dose [1]. The drug targets a T-cell to B-cell costimulation pathway that earlier antibodies could not safely engage because of thromboembolic events, and Sanofi has redesigned the Fc region of the antibody to blunt that liability. Phase 3 enrollment on the relapsing arm is complete and readouts sit in the 2027 window [2]. Approval in progressive MS, where almost nothing works today, would be a franchise-defining outcome for Sanofi's neuroscience unit and the first regulatory validation of the anti-CD40L class after three decades of failure. Beyond MS, Sanofi is running parallel Phase 2 programs in type 1 diabetes (FABULINUS) [3], focal segmental glomerulosclerosis [4], and kidney transplant rejection [5], giving frexalimab optionality across five autoimmune and alloimmune indications on a single biologic.

First-in-indication for CD40L blockade in multiple sclerosis. FREXALT (NCT06141473, n=1,655) enrolled adult patients with relapsing MS against an active comparator of oral teriflunomide 14 mg daily and moved to ACTIVE_NOT_RECRUITING, meaning enrollment is done and the clock is running on annualized relapse rate as the primary endpoint [2]. FREVIVA (NCT06141486, n=858) is the parallel Phase 3 in non-relapsing secondary progressive MS, placebo-controlled, with time to 6-month confirmed disability progression as the primary endpoint; the trial is also ACTIVE_NOT_RECRUITING as of 2026 with a start date of December 2023 [9]. No public FDA designations have been disclosed for either arm (no breakthrough, fast track, or priority review), which is unremarkable for FREXALT (relapsing MS is a crowded market) but arguably notable for FREVIVA given the high unmet need in non-relapsing SPMS, where no disease-modifying therapy is currently approved. Sanofi is also pushing a subcutaneous formulation into a Phase 3 non-inferiority study against IV (NCT07325292, n=160) [6] and running Phase 2s in type 1 diabetes (FABULINUS, NCT06111586, n=197) with mixed meal tolerance test C-peptide as the primary readout [3], primary focal segmental glomerulosclerosis and minimal change disease (NCT06500702) [4], and kidney transplant rejection (NCT07412470, n=526, non-inferiority to tacrolimus) [5]. Phase 3 MS readouts are not expected until 2027 given the observation windows required for ARR and confirmed disability progression endpoints. Frexalimab has an assigned RxNorm CUI (2686253), reflecting formal recognition as a clinical-stage drug identity by the National Library of Medicine.

CD40L is a protein on the surface of T cells that shakes hands with CD40 on B cells and other immune cells. That handshake is one of the loudest "go" signals in the immune system: it licenses B cells to make antibodies, keeps T cells activated, and turns up the innate immune cells that drive tissue damage in autoimmunity. Cutting the wire dampens the whole cascade upstream of the individual cell types that current MS drugs target. Anti-CD20 drugs like ocrelizumab wipe out B cells wholesale; anti-CD40L leaves the B cells alive but silenced, which theoretically preserves vaccine responses and infection defense. The pathway is validated by human genetics. People born with loss-of-function mutations in CD40LG develop hyper-IgM syndrome, an immune deficiency, rather than autoimmunity, which tells you the pathway is genuinely load-bearing for immune activation (Open Targets evidence scores 0.84 for hyper-IgM associations). But the story has scars. First-generation anti-CD40L antibodies (ruplizumab, IDEC-131) triggered thromboembolism in lupus trials 20 years ago because their Fc region cross-linked platelets via FcγRIIa, effectively gluing platelets together. Frexalimab was engineered with a silent Fc that does not bind platelet FcγRIIa. Clean Phase 2 safety on the thrombosis front is the whole reason this drug got to Phase 3 and the whole class got a second life [1].

FREXALT (NCT06141473) is a Phase 3 study in relapsing MS enrolling 1,655 patients with annualized relapse rate (the average number of documented relapses a patient experiences per year, where current top MS drugs reduce this by roughly 50 to 70% versus placebo) as the primary endpoint against an active comparator of oral teriflunomide 14 mg daily [2]. Teriflunomide is a moderate-efficacy oral DMT, which means a statistical win is plausible but the label will be commercially weaker than a head-to-head win against ocrelizumab would have been. The study is now ACTIVE_NOT_RECRUITING, meaning the enrollment target has been hit. FREVIVA (NCT06141486) is the parallel Phase 3 in non-relapsing secondary progressive MS, enrolling 858 adults with EDSS 3.0 to 6.5 and no relapses for at least 24 months, with time to 6-month confirmed disability progression as the primary endpoint, an endpoint where success is historically rare [9]. Beyond MS, Sanofi is running FABULINUS (NCT06111586, n=197) to test whether frexalimab preserves endogenous insulin secretion in recent-onset type 1 diabetes, measured by change in mixed meal tolerance test C-peptide AUC at week 52 in adolescents and adults on insulin therapy [3][7]. The kidney transplant trial (NCT07412470, n=526) benchmarks against tacrolimus, the current standard anti-rejection drug (a calcineurin inhibitor that dampens T-cell activation), with a composite of biopsy-proven acute rejection, graft loss, and death at 1 year [5], a bold non-inferiority swing given tacrolimus is the backbone of modern transplantation. The FSGS/minimal change disease Phase 2 (NCT06500702) uses percent reduction in urine protein-to-creatinine ratio, a validated efficacy signal for glomerular disease [4]. The subcutaneous bridging study (NCT07325292) is the commercial linchpin because IV-only administration would gut the drug's competitive position against oral DMTs and subcutaneous ocrelizumab [6].

Our model estimates a 20% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by heavier-than-usual blinding, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The dominant risk is mechanism-class thromboembolism. First-generation anti-CD40L antibodies were terminated because they caused clots via platelet FcγRIIa cross-linking. Frexalimab's silent Fc should prevent that, and Phase 2 data through 24 weeks looked clean [1], but the confirmation window is a multi-year Phase 3 in a much larger patient base. A single unexplained pulmonary embolism cluster would be catastrophic for the program and the class. Efficacy risk splits by indication. FREXALT hits an endpoint (annualized relapse rate) that current DMTs already suppress by 50% to 70%, and the comparator is teriflunomide, a moderate-efficacy oral. Beating teriflunomide is very achievable but the resulting label is commercially weaker than a head-to-head win against ocrelizumab would have been, because clinicians will still ask how frexalimab compares to the anti-CD20 standard of care. FREVIVA has to hit disability progression in non-relapsing progressive MS, an endpoint that has broken almost every sponsor that has tried it and where no DMT is currently approved. The absence of any disclosed FDA breakthrough or fast track designation for FREVIVA, despite the profound unmet need in that indication, is worth flagging: it may reflect the agency's caution about the CD40L class safety history, or simply that Sanofi did not seek it. Commercial risk is real even on a clean win. Ocrelizumab loses exclusivity in the late 2020s, and biosimilar anti-CD20s will pressure any premium-priced newcomer. Sanofi will need a clean differentiation story (no infusion reactions, no B-cell depletion infection profile, preserved vaccine responses) to justify pricing. Frexalimab is a biologic with expected data exclusivity of 12 years in the US and 10 years in the EU from first approval, so the biosimilar horizon is well into the late 2030s assuming a 2028 launch. Execution risk on the T1D, FSGS, and transplant programs is lower because Phase 2 is exploratory, but a negative safety readout in any of those indications spills back onto the MS program because the FDA reviews the whole file.

Signal. Frexalimab is one of the more scientifically interesting MS bets on the board because it targets a pathway upstream of the anti-CD20 strategy that has come to dominate the market, and because the same drug is being tested in indications (type 1 diabetes, kidney transplant, FSGS) where success would open non-overlapping billion-dollar franchises. The mechanism-class thrombosis scar is a real gating question and Phase 3 duration is where that risk crystallizes. The specific data point to watch is any interim safety disclosure from FREXALT or FREVIVA, particularly around thromboembolic adverse events. The subcutaneous bridging readout (NCT07325292) matters commercially [6]: an SC-approved regimen changes the drug's positioning against oral DMTs and self-administered ocrelizumab. For Sanofi (2024 net sales of €41.1 billion, roughly $44 billion USD at 2024 average FX) [8], a Phase 3 win in both MS indications plus a positive T1D disease-modification signal from FABULINUS would define the neuroscience franchise for the next decade. FABULINUS primary completion is April 2027 per ClinicalTrials.gov, so the earliest meaningful test of whether the mechanism travels beyond MS is roughly 8 months out from this writeup and represents the next concrete catalyst on the program calendar.